Whereas E2F1, MDK, BIRC5, IL10, PGR, C1orf35 and TFCP2 (among others) seem to represent promising targets for intervention in all HCCs, therapy directed against KIFC1, PAFAH1B3, PKMYT1, PEG10, PARP1, POU2F1, NFY or TNF might be effective specifically in advanced GE2-HCC. Here, PEG10 is linked to hepatocellular carcinoma.